FLOVENT Drug Patent Profile
✉ Email this page to a colleague
When do Flovent patents expire, and when can generic versions of Flovent launch?
Flovent is a drug marketed by Glaxosmithkline and Glaxo Grp Ltd and is included in four NDAs. There is one patent protecting this drug.
The generic ingredient in FLOVENT is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Flovent
A generic version of FLOVENT was approved as fluticasone propionate by FOUGERA PHARMS on May 14th, 2004.
Summary for FLOVENT
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 86 |
| Clinical Trials: | 38 |
| Patent Applications: | 5,456 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for FLOVENT |
| Drug Sales Revenues: | Drug sales revenues for FLOVENT |
| What excipients (inactive ingredients) are in FLOVENT? | FLOVENT excipients list |
| DailyMed Link: | FLOVENT at DailyMed |
Recent Clinical Trials for FLOVENT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Glenmark Pharmaceuticals Ltd. India | Phase 3 |
| Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Respirent Pharmaceuticals Co Ltd. | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for FLOVENT
US Patents and Regulatory Information for FLOVENT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | FLOVENT | fluticasone propionate | AEROSOL, METERED;INHALATION | 020548-001 | Mar 27, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Glaxo Grp Ltd | FLOVENT DISKUS 100 | fluticasone propionate | POWDER;INHALATION | 020833-002 | Sep 29, 2000 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Glaxosmithkline | FLOVENT | fluticasone propionate | POWDER;INHALATION | 020549-001 | Nov 7, 1997 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FLOVENT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline | FLOVENT | fluticasone propionate | AEROSOL, METERED;INHALATION | 020548-003 | Mar 27, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Glaxosmithkline | FLOVENT | fluticasone propionate | POWDER;INHALATION | 020549-001 | Nov 7, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| Glaxosmithkline | FLOVENT | fluticasone propionate | AEROSOL, METERED;INHALATION | 020548-001 | Mar 27, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for FLOVENT
See the table below for patents covering FLOVENT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Ireland | 51395 | STEROIDS OF THE ANDROSTANE SERIES | ⤷ Try a Trial |
| Spain | 532055 | ⤷ Try a Trial | |
| Ecuador | SP941097 | CARBOTIOATOS DE ADROSTANO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FLOVENT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2506844 | 1890025-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117 |
| 1305329 | SPC/GB08/026 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116 |
| 1519731 | 13C0067 | France | ⤷ Try a Trial | PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
